Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06136546 · ClinicalTrials.gov registry record · Phase 2
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
A Phase 2 study of Inflammation and Depressive Disorder, Major, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06136546: Recruiting Phase 2 study of Inflammation and Depressive Disorder, Major, sponsored by Massachusetts General Hospital.
NCT06136546 is a Phase 2 study of Inflammation and Depressive Disorder, Major that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06136546, a Phase 2 study of Inflammation and Depressive Disorder, Major, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.
Primary Outcome
Faster within-person psychomotor speed (i.e. median response time)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Infliximab
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2029-01-31 |
| Phase | Phase 2 |
What NCT06136546 shows while recruiting
NCT06136546 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06136546 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06136546 about?
NCT06136546 is a clinical study titled "Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab". This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.
What is the current status of trial NCT06136546?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-01-23. Estimated completion is 2029-01-31.
What conditions does trial NCT06136546 study?
This clinical trial studies the following conditions: Inflammation, Depressive Disorder, Major.
What interventions are being tested in trial NCT06136546?
The interventions under investigation include: Placebo (OTHER), Infliximab (DRUG).
Who is sponsoring clinical trial NCT06136546?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06136546 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06136546's enrollment target sits among peer trials
100 45th of 132 higher than 85 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
-
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Modulating Exercise Dosage to Improve Concussion Recovery
RECRUITING · Phase 2
-
Passive Stretching in Peripheral Arterial Disease Patients
RECRUITING · Phase 2
-
Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI